唑来膦酸在老年女性骨质疏松患者全髋置换术后的应用
发布时间：2019-05-10 13:56
【摘要】：目的：研究老年女性骨质疏松症合并髋关节病患者行全髋关节置换术后急性期内应用唑来膦酸的疗效及安全性。方法：选择2009年1月至2010年1月因髋部骨折或股骨头无菌性坏死而住院接受全髋关节(非骨水泥型假体)置换术的老年女性患者,根据骨密度(BMD)检测结果选取骨质疏松症患者148例,随机分为治疗组和对照组,2组患者手术后均接受钙剂和骨化三醇治疗,治疗组于术后1～2周给予唑来膦酸5mg静脉滴注,以后每年给药1次,连续3年,对照组在治疗组用药同期给予相同体积的0.9%氯化钠注射液。每年复查并记录腰椎及健侧髋部骨密度变化,观察术后3年内假体周围骨折及假体是否有无菌性松动。结果：连续治疗3年后治疗组骨密度较用药前提高,差异有统计学意义(P0.05),对照组用药前后骨密度差异无统计学意义(P0.05)；术后3年内治疗组假体周围骨折及假体无菌性松动发生的例数均低于对照组。2组用药后不良反应发生率差异无统计学意义(P0.05)。结论：骨质疏松患者行关节置换术后急性期内使用唑来膦酸安全有效,可提高骨密度,且可能减少假体周围骨折和假体松动的发生。
[Abstract]:Objective: to study the efficacy and safety of zoledronic acid in elderly female patients with osteoporosis complicated with hip arthropathy after total hip arthroplasty. Methods: from January 2009 to January 2010, elderly female patients who underwent total hip arthroplasty due to hip fracture or aseptic necrosis of the femoral head were selected. According to the results of bone mineral density (BMD), 148 patients with osteoporosis were randomly divided into treatment group and control group. The patients in both groups were treated with calcium and ossified triol after operation. The treatment group was given zoledronic acid 5mg intravenously at 1 and 2 weeks after operation, and then once a year for 3 years. The control group was given 0.9% sodium chloride injection of the same volume at the same time. The changes of bone mineral density (bone mineral density) of lumbar vertebrae and healthy hip were reviewed and recorded every year to observe the fracture around the prosthesis and aseptic loosening within 3 years after operation. Results: after 3 years of continuous treatment, the bone mineral density of the treatment group was significantly higher than that before treatment, the difference was statistically significant (P 0.05), but there was no significant difference in the bone mineral density of the control group before and after treatment (P 0.05). Within 3 years after operation, the number of cases of periprosthetic fracture and aseptic loosening in the treatment group was lower than that in the control group. There was no significant difference in the incidence of adverse reactions between the two groups (P 0.05). Conclusion: zoledronic acid is safe and effective in patients with osteoporosis after joint replacement. Zoledronic acid can increase bone mineral density and reduce the occurrence of fracture and loosening around the prosthesis.
【学位授予单位】：新疆医科大学
【学位级别】：硕士
【学位授予年份】：2015
【分类号】：R687.4
，
本文编号：2473696
[Abstract]:Objective: to study the efficacy and safety of zoledronic acid in elderly female patients with osteoporosis complicated with hip arthropathy after total hip arthroplasty. Methods: from January 2009 to January 2010, elderly female patients who underwent total hip arthroplasty due to hip fracture or aseptic necrosis of the femoral head were selected. According to the results of bone mineral density (BMD), 148 patients with osteoporosis were randomly divided into treatment group and control group. The patients in both groups were treated with calcium and ossified triol after operation. The treatment group was given zoledronic acid 5mg intravenously at 1 and 2 weeks after operation, and then once a year for 3 years. The control group was given 0.9% sodium chloride injection of the same volume at the same time. The changes of bone mineral density (bone mineral density) of lumbar vertebrae and healthy hip were reviewed and recorded every year to observe the fracture around the prosthesis and aseptic loosening within 3 years after operation. Results: after 3 years of continuous treatment, the bone mineral density of the treatment group was significantly higher than that before treatment, the difference was statistically significant (P 0.05), but there was no significant difference in the bone mineral density of the control group before and after treatment (P 0.05). Within 3 years after operation, the number of cases of periprosthetic fracture and aseptic loosening in the treatment group was lower than that in the control group. There was no significant difference in the incidence of adverse reactions between the two groups (P 0.05). Conclusion: zoledronic acid is safe and effective in patients with osteoporosis after joint replacement. Zoledronic acid can increase bone mineral density and reduce the occurrence of fracture and loosening around the prosthesis.
【学位授予单位】：新疆医科大学
【学位级别】：硕士
【学位授予年份】：2015
【分类号】：R687.4
，
本文编号：2473696
本文链接：https://www.wllwen.com/yixuelunwen/waikelunwen/2473696.html
最近更新
教材专著
